Treatment guides

Proton therapy has a 5-year survival rate of 95% or higher in prostate cancer patients. Proton therapy has been used on more than 170,000 people around the world. The success rate of proton therapy for prostate cancer varies from 76-99%. More than 1000 new articles appeared due to the clinical studies last year.

About 73% of lutetium 177 vipivotide tetraxetan patients saw their prostate-specific antigen (cancer marker) drop. Compared to the standard treatment, the lu 77 Pluvicto therapy had a 38% lower chance of dying and a 60% —of getting worse. Nearly 30% of men treated with Pluvicto plus BSoC had their tumor shrink, and 6% of tumors disappeared.

Patients with localized or regional prostate tumors have a nearly 100% of 5-year survival rate. After a low-dose rate (LDR) procedure, the radiation stays active for about 10-12 months. Up to 90% of men, after the prostate brachytherapy procedures, can keep their erections.

A new surgery that uses a da Vinci machine begins every minute somewhere in the world. Da Vinci shows 3D images in HD quality, ten times greater than the human eye can see. By 2014, up to 90% of radical prostatectomies in the US were done with robot assistance.

With SIRT and chemotherapy, the average length of life is more than twice, compared to chemotherapy alone. The liver after Y-90 cancer treatment will improve in about 70% to 95% of the patients. With small liver tumors that couldn't be cut out, the radioembolization’s response rate was 88%.

Microwave ablation of liver tumors takes less than 10 minutes, usually 2-5 minutes. If the tumor is 2 cm or less, the 5-year survival is 80%-90% after cancer ablation. The microwave liver ablation success rate is more than 85%. Only 20% of people with liver metastases can be treated with surgery; ablation can help many of them if tumors are less than 3 cm.